Mean BCVA at baseline was 81.9 letters in the PRP group and 80.9 letters in the aflibercept group. Visual outcomes are presented as the adjusted difference between groups, accounting for baseline differences in BCVA. There were no reported cases of endophthalmitis in either group. PDR – proliferative diabetic retinopathy; PRP – panretinal photocoagulation; DM – diabetes mellitus; VEGF – vascular endothelial growth factor; CRT – central retinal thickness; PRN – pro re nata (i.e. as needed); BCVA – best corrected visual acuity; ETDRS – early treatment diabetic retinopathy study; CI – confidence interval; adj. – adjusted.
Reference: Sivaprasad et al. “Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.” Lancet, 2017 Jun 3;389(10085):2193–2203.
Funding
Medical Research Council UK (MR/R000735/1).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Please note that the infographic is best viewed online.
Rights and permissions
About this article
Cite this article
Yusuf, I.H., Henein, C. & Sivaprasad, S. Infographic: Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation in patients with proliferative diabetic retinopathy (PDR): the CLARITY study. Eye (2023). https://doi.org/10.1038/s41433-023-02391-5
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-023-02391-5